Duloxetine: Clinical Overview
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, with a generally favorable safety profile when dosed appropriately.
FDA-Approved Indications
Duloxetine is indicated for 1:
- Major Depressive Disorder (MDD) in adults
- Generalized Anxiety Disorder (GAD) in adults and pediatric patients ≥7 years
- Diabetic Peripheral Neuropathic Pain (DPN)
- Fibromyalgia
- Chronic Musculoskeletal Pain
Note: Duloxetine is not approved for pediatric MDD despite clinical trial data 1.
For neuropathic pain specifically, duloxetine is a first-line agent alongside tricyclic antidepressants, gabapentin, and pregabalin 2.
Recommended Dosing
For Neuropathic Pain
- Start: 30 mg once daily for 1 week
- Target: 60 mg once daily 2
- Maximum: 60 mg once daily (higher doses not more effective for neuropathic pain)
- Duration of adequate trial: 6-8 weeks with at least 2 weeks at maximum tolerated dose 2
This gradual titration significantly reduces nausea, the most common adverse effect 2, 3.
For Depression/Anxiety
- Start: 30-40 mg daily
- Target: 60 mg once daily (as effective as 60 mg twice daily) 2
- Maximum: 120 mg/day (can be split into two doses) 4
Administration Details
- Swallow capsules whole—do not chew, crush, or open 1
- Can be taken with or without food 1
- If dose missed, take as soon as remembered unless near next dose; never double dose 1
Absolute Contraindications
1:
- Concurrent MAOI use or within 14 days of discontinuing MAOI (risk of serotonin syndrome/hypertensive crisis)
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment
- Severe renal impairment (CrCl <30 mL/min) 4
- Concurrent use with thioridazine (risk of serious arrhythmias/sudden death)
Critical Warnings and Precautions
Black Box Warning
Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (especially first few months of treatment). Monitor closely for clinical worsening, suicidality, or unusual behavior changes 1.
Serious Adverse Effects Requiring Monitoring
Hepatotoxicity 1:
- Monitor for jaundice, right upper quadrant pain, dark urine
- However, routine aminotransferase monitoring is not necessary per recent reviews 2
Blood Pressure Changes 1:
- Can cause hypertension or orthostatic hypotension
- Monitor BP before starting and throughout treatment
- Increased fall risk in elderly
Serotonin Syndrome 1:
- Life-threatening when combined with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl, St. John's Wort)
- Symptoms: agitation, hallucinations, tachycardia, hyperthermia, hyperreflexia, muscle rigidity, seizures
Bleeding Risk 1:
- Increased with concurrent NSAIDs, aspirin, or warfarin
- Monitor for bruising/bleeding
Severe Skin Reactions 1:
- Stevens-Johnson syndrome possible
- Discontinue immediately if blistering, peeling rash, or mouth sores develop
Hyponatremia 1:
- Elderly at higher risk
- Monitor for headache, confusion, weakness, unsteadiness
Common Adverse Effects
Most Frequent (>10% incidence) 1, 3:
- Nausea (18% in pediatrics, most common overall)
- Dry mouth
- Somnolence/fatigue
- Constipation
- Decreased appetite/weight loss (especially pediatrics: 14% vs 6% placebo)
- Dizziness
- Hyperhidrosis
Management Strategy
Nausea is dose-dependent and significantly reduced by starting at 30 mg daily for 1 week before advancing to 60 mg 2, 3. This is the single most important tolerability measure.
Pediatric-Specific Concerns 1:
- Weight loss: 16% experienced ≥3.5% weight loss (vs 6% placebo)
- Height: Mean 1% decrease in height percentile over 9 months
- Monitor weight and height regularly in pediatric patients
Discontinuation Syndrome
Never stop abruptly—taper gradually 1. Withdrawal symptoms include:
- Headache, dizziness, insomnia
- Irritability, anxiety
- Electric shock-like sensations
- Nausea, vomiting
- Sweating
Drug Interactions
Major Interactions 1:
- CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): Avoid combination
- CYP2D6 substrates: Duloxetine is a moderate CYP2D6 inhibitor 5—reduce doses of drugs metabolized by 2D6 (e.g., propafenone, flecainide)
- Serotonergic drugs: High risk of serotonin syndrome
- Alcohol: Avoid heavy use (risk of severe liver injury) 1
Favorable Interaction Profile
Duloxetine does not significantly inhibit CYP3A4, 1A2, 2C9, or 2C19 6, making it preferable when drug-drug interactions are a concern (though less favorable than venlafaxine/desvenlafaxine in this regard) 5.
Clinical Efficacy Context
For neuropathic pain, duloxetine demonstrates:
- Consistent efficacy in diabetic peripheral neuropathy with sustained benefit up to 1 year 2
- Pain relief can occur within 1 week at 60 mg/day 3
- Efficacy in other neuropathic pain types is unknown (not studied) 2
For depression, duloxetine achieves remission rates similar to SSRIs 7 and is particularly useful for patients with comorbid painful physical symptoms 7, 8.
Special Populations
Pregnancy/Breastfeeding 1:
- Notify provider immediately if pregnant
- Passes into breast milk—discuss risks/benefits
Elderly 9:
- Higher risk of hyponatremia, falls, orthostatic hypotension
- Consider lower starting doses
- Monitor BP and sodium closely
Renal/Hepatic Impairment:
Practical Prescribing Algorithm
- Screen for contraindications: MAOIs, glaucoma, severe renal/hepatic disease
- Baseline assessment: BP, weight (especially pediatrics), psychiatric status
- Start low: 30 mg daily × 7 days to minimize nausea
- Titrate to target: 60 mg daily (most effective dose for pain and depression)
- Assess at 2 weeks: If inadequate response, ensure compliance and consider adding another first-line agent for neuropathic pain 2
- Adequate trial: 6-8 weeks before declaring treatment failure 2
- Monitor ongoing: BP, weight (pediatrics), suicidality, bleeding if on anticoagulants